Impact of the World Trade Organization TRIPS agreement on the pharmaceutical industry in Thailand.

Impact of the World Trade Organization TRIPS Agreement on the pharmaceutical industry in Thailand Siripen Supakankunti,1 Wattana S. Janjaroen,2 Oranee Tangphao,3 Sauwakon Ratanawijitrasin,4 Paitoon Kraipornsak,1 & Pirus Pradithavanij5 The 1994 World Trade Organization (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) established minimum universal standards in all areas of intellectual property. It is intended to implement these standards globally through a WTO enforcement mechanism. The present article proposes a strategy for alleviating the potentially negative impact of TRIPS in Thailand in relation to the following: purchasers; prescribers and dispensers; producers; products; price control; patent-to-third-party; parallel imports; power of the customer; patentable new drugs; personnel; and prevention policies. The following TRIPS provisions are pertinent to the pharmaceutical industry in Thailand: the limited term of product and process patents; the conditions of protection; and the broad scope for compulsory licensing and enforcement procedures in the national patent system. Keywords Drug industry; Commerce; Drug costs; Legislation, Drug; Patents; Treaties; Thailand (source: MeSH ). Mots cle´s Industrie pharmaceutique; Commerce; Couˆt me´dicament; Le´gislation pharmaceutique; Brevet; Thaı¨lande (source: INSERM ). Palabras clave Industria farmace´utica; Comercio; Costos en drogas; Legislacio´n de medicamentos; Patentes; Tailandia (fuente: BIREME ). Bulletin of the World Health Organization, 2001, 79: 461–470. Voir page 470 le re´sume´ en franc¸ais. En la pa´gina 470 figura un resumen en espan˜ol. Introduction In 1947, a total of 23 countries signed the General Agreement on Tariffs and Trade (GATT). The primary objective was to promote and regulate the liberalization of international trade through rounds of trade negotiations. Between 1986 and 1994 the Uruguay Round of Multilateral Trade Negotiations led to the Marrakech Agreements. These established the World Trade Organization (WTO) and extended the rules governing commercial relations between trading partners to a number of new areas, such as agriculture, services, investment measures and the protection of intellectual property rights. All of these areas had previously been excluded from trade liberalization. Since 1994, attention has focused on the WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) as the most far-reaching international instrument ever negotiated in this field. It establishes minimum universal standards in all areas of intellectual property and the intention is to implement these standards globally through a strong enforcement mechanism established in WTO. The TRIPS agreement requires universal patent protec- tion for any invention in any field of technology. This affects pharmaceuticals, which many countries had previously excluded from patent protection in order to produce drugs at reduced prices and thereby contribute to the improvement of public health. WTO member countries that did not previously recognize pharmaceutical patents must amend their patent legislation within a limited time or transition period. Any member country failing to bring its patent law into conformity with the TRIPS agree- ment, if challenged by another member country, is subject to the WTO dispute settlement system. Sanctions may be established in accordance with WTO procedures. The TRIPS patent system can be expected to have a great impact on the health sector and may negatively affect national drug production, drug prices, the availability of essential medicines and 1 Director, Centre for Health Economics, Faculty of Economics, Chulalongkorn University, Bangkok 10330, Thailand (email: ssiripen@chula.ac.th). Correspondence should be addressed to Professor Supakankunti. 2 Associate Professor, Faculty of Economics, and Associate Dean to the College of Public Health, Chulalongkorn University, Bangkok, Thailand. 3 Assistant Professor, Department of Pharmacology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. 4 Assistant Professor, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand. 5 Director, Air Force Base 53 Hospital, Prachuab Khiri Khan Province, Thailand. Ref. No. 00-0546 461Bulletin of the World Health Organization, 2001, 79 (5) # World Health Organization 2001 pharmaceutical technology, and numerous other factors in developing and least developed countries. In addition, there could be a greater concentration of drug production in industrial countries rather than a transfer of technology to, or foreign direct invest- ment (FDI) in developing countries. No extensive review of the practical implica- tions of the TRIPS agreement has been conducted at the global and national levels, and at the regional level only Latin America has been covered. The present paper examines the consequences of the agreement for the pharmaceutical industry in Thailand with a view to learning lessons applicable to all developing countries. Recommendations are given for alleviating the potential negative impact resulting from man- dates set forth in the agreement. In order to determine the specific implications and potential consequences accurately and meaning- fully, we identified applicable and clearly defined objectives. Relevant research methods were em- ployed, including situation and data analyses, surveys and impact assessments, and literature reviews. The situation and data analyses and the impact assess- ments dealt with the effect of the 1992 Thai Patent Law on the pharmaceutical industry in Thailand and on direct foreign investment and the transfer of technology in the sector. For the first time this law covered the protection of rights for both pharma- ceutical processes and products. Objectives The objectives of the study were to review the impact of the 1992 Thai Patent Law on the pharmaceutical industry in Thailand, the FDI situation, and the transfer of technology in the sector. This involved the following steps: 1) a review of the increase in drug prices associated with patented drugs and of the increase in foreign exchange costs of imports attributable to the increased price of drugs after the Patent Act became effective in September 1992; 2) a review of the proportion of patented and generic drugs on the market and of the effectiveness of the drug price control system in Thailand; and 3) identi- fication of those aspects of the Patent Act requiring changes in the light of findings under 1) and 2) above, and recommendations on the health sector’s partici- pation in the process of effecting improvements/ changes in the Patent Act that could be considered by national and international health authorities to safe- guard health interests. Methods The methodology used to prepare this case study consisted of a situation analysis based on a literature review of relevant research, data and statistical analyses, impact assessments, and surveys. Although there has been no extensive review of the practical implications of the TRIPS agreement on the pharma- ceutical industry, there have been many studies on subcomponents of the larger issue. Several such studies specific to Thailand were used for this assessment, including key empirical studies on experience in procurement systems and drug prices. Among the data and statistical analyses were reviews of the prices, quantities and values of imported drugs, the market value of the pharmaceutical sector, and the ratio of total manufacture to imports of modern medicines registered in Thailand. Several impact assessments were conducted, comparing the import and export value of medicinal and pharmaceutical products in Thailand, the real performances of leading generic and originator pharmaceutical companies, and the nominal and real prices of selected pharmaceu- ticals. The market value of the pharmaceutical sector was reviewed and a comparison was made of share values of pharmaceutical trading companies with reference to the citizenship of shareholders. Surveys were conducted in order to complete the overall situation analysis. Prominent among these were surveys on the opinions of executives concerning factors influencing price policy. On the basis of the work done and previous studies it was possible to arrive at a general overview. This allowed conclusions to be drawn and strategies to be derived for dealing with the impact of the TRIPS agreement on the country’s pharmaceutical industry. Situation analysis Thailand’s first patent law was enacted in 1979. It received little attention from government because of a misunderstanding that patent law applied only to industrialized countries and created a monopoly, and therefore that it was inappropriate for an agricultural country. As a result there were many problems and the 1979 law was therefore revised in 1992 to include the protection of rights for both pharmaceutical processes and products. In 1999 a third patent law included changes to the 1992 law and clarification of enforcement provisions. Major revisions allowed petty patents (which protect simple inventions that have industrial applicability), pipeline protection and parallel imports. The intention is to give Thai and foreign inventors an alternative to intellectual property rights protection. The process of obtaining a petty patent is shorter than that for a regular patent but the period of protection is also shorter — six years instead of twenty. Pipeline protection for patent holder countries stemmed from the controversy about the effect of the 1992 patent law on drug prices. The increase in drug prices caused difficulty for Thai pharmaceutical companies that could no longer import previously unprotected and inexpensive raw material to produce drugs. This meant that the Thai drug production market could not be developed. Outside forces compelled the government to extend patent protection to drug companies situated in other countries. The revision of the second Thai patent law stipulated that drugs granted patent rights in other 462 Bulletin of the World Health Organization, 2001, 79 (5) Policy and Practice countries between 1 January 1986 and 30 September 1991 would be protected in Thailand for 5–6 years, but not for longer than the period registered in the originator country. This is termed pipeline protection for the patent holder country. The third major revision allowed parallel importation, whereby drugs belonging to a patent holder can be imported by another person, provided that the patent owner manufactures the drug or has granted a licence to manufacture it in another country. Many people advocate that the revision of the drug patent law to coincide with TRIPS should emphasize the right of the Thai people to the benefits of patented drugs. In Thailand the TRIPS agreement could lead to an increase in the price of patented drugs and in the amount of patent royalties. There could also be a concentration of drug production in industrialized countries rather than technology transfer to, or FDI in developing countries. In addition, the new WTO patent system cannot be expected to increase research or development in developing countries. However, it has been argued that the protection of pharmaceuticals will enhance the tendency to transfer technology; that there will be an increase in FDI, benefiting developing countries; and that the increase in resources devoted to research and development by local pharmaceutical companies will lead to the development of new drugs suited to their own situations, to products of improved quality, and to an end to the brain drain in Thailand (1–3). The potential effects of the TRIPS provisions on the pharmaceutical industry in Thailand relate to the limited terms of product and process patents, the conditions of protection, and the broad scope for compulsory licensing and enforcement procedures in the national patent system (4). The findings of the present study on the implications of the TRIPS agreement for the Thai pharmaceutical industry are discussed below. Technology transfer and FDI There has not been much technology transfer to or FDI in the Thai pharmaceutical industry since 1992. The industry is still rather small compared with other production sectors and is concerned with domestic consumption rather than export.Moreover, 48.5%of the raw material and intermediate input for this industry was imported for domestic production. In addition, the data on Thai pharmaceutical companies registered from 1984 to 1998 indicated that there were more Thai than foreign shareholders, reflecting the fact that little FDI is flowing into the industry (see Tables 1–3). Spending on health care Spending on health care is mainly for curative purposes. A great deal of this expenditure is for medical technologies, including medication, the rate of which is rising faster than overall health care spending. This is because both hospitals and pharmacies provide diagnosis and a normal supply of medicines. Many drugs that require a prescription in developed countries are sold freely in Thailand. Also, there are dispensing regulations for certain drugs but they are often ignored. Drug registration The current drug registration system has been in place since 1992. A new feature of the system is the Safety Monitoring Programme (SMP). This requires that any new drug be used under the supervision of physicians for a minimum of 2 years, and that the licensee report any safety problems associated with its use. The SMP also stipulates that no othermanufacturer is allowed to produce drugs covered by the SMP. Consequently, the SMP serves to uphold patent protection. Up to 30 December 1998, a total of 705 drug items had been registered under the new drug approval system giving the benefit of the SMP to patent holders. Of these items, 423 are still covered by the SMP, while for 282 the safety monitoring period has already elapsed. Generic pharmaceutical companies Before 1989, generic pharmaceutical companies did better than originator firms in terms of operational income generated from one unit of assets. Subse- quently, the reverse was true, perhaps because foreign- owned companies performed better than Thai-owned firms. However, some medicines and types of health caremay be luxuries rather than necessities. During the period of economic prosperity in Thailand in the late 1980s, many people could afford to purchase medicines or health services that they perceived to be of high quality, and many used imported drugs. In Thailand there is a tendency to spend more on imported drugs than on those produced in the country, and the rate of increase in expenditure on imported drugs by Thais is higher than the rate of income growth (Fig. 1, Table 4 and Table 5). Impact of economic crisis The impact of the economic crisis on the cost of imported drugs has caused the government to control Table 1. Revealed comparative advantage of medicinal and pharmaceutical products in selected countries, 1984–95a Year Germany Switzerland USA Thailand Singapore Malaysia 1984 1.6481 7.6069 1.6578 0.1839 0.6625 0.1547 1985 1.5628 7.0899 1.6214 0.1738 0.7209 0.1381 1986 1.4028 6.5404 1.5582 0.1307 0.6231 0.1544 1987 1.4128 6.7897 1.3661 0.1275 0.5193 0.1432 1988 1.3565 6.0789 1.2263 0.1350 0.4153 0.1272 1989 1.3610 6.3652 1.0024 0.1020 0.4052 0.1246 1990 1.3389 6.2200 0.9677 0.1068 0.3615 0.1154 1991 1.3499 6.2582 0.9175 0.1313 0.2865 0.0848 1992 1.2739 6.3614 0.8947 0.1313 0.2865 0.0848 1993 1.4124 6.3297 0.8879 0.2411 0.3542 0.0761 1994 1.4361 6.3093 0.8472 0.1350 0.3586 0.0812 1995 1.3802 6.4269 0.7735 0.1534 0.3498 0.0748 a See ref. 4. 463Bulletin of the World Health Organization, 2001, 79 (5) Impact of TRIPS on the pharmaceutical industry in Thailand spending on healthmore stringently. This has involved the introduction of an essential drugs policy and the more common use of generic drugs, as happened in 1998. It is worth considering whether such a policy would be sound following economic recovery. Policy- makers will have to determine the grounds on which government control of spending is warranted and whether such control is effective when people can afford to buy higher-priced products. The reduction in the import value of finished drugs, mostly originals, in 1998, can be explained by at least three factors: the price effect, attributable to the depreciation of the baht; the income effect; and government policy favouring domestically produced drugs. These factors are interconnected and difficult to separate. The 1992 Patent Act Since the 1992 Patent Act went into effect, the share of original drugs in the Thai market increased by 1–6% per year, reaching a peak in 1997, when the shares of generic and original products were 33% and 67%, respectively. Until 1997 the growth rate of the originator market was two to three times that of gross domestic product (GDP). It seemed that the originator sector was not affected by the financial crisis in mid-1997, when the baht was floated. However, when the effect of the exchange rate was taken into account, the market value of the originator sector began shrinking in 1997: the total volume in US$ decreased by 17% and 24% in 1997 and 1998, respectively. In 1998, original drugs lost 13.3% of their share; nonetheless, they still dominated the market with more than 50% of the total. Generally, the Thai market continues to be segmented between original and generic drugs, with the substitution effect, to Table 2. Share of foreign direct investment (FDI) in Thai industry, 1988–98a Year Industry Chemicals Total FDI Share (%) (baht 6 106) (baht 6 106) (baht 6 106) Industry/ Chemicals/ Chemicals/ total total industry 1988 16 162.4 1 059.7 27 963.5 57.8 3.8 6.6 1989 21 866.1 2 818.5 45 697.6 47.8 6.2 12.9 1990 29 071.4 4 293.2 62 516.3 46.5 6.9 14.8 1991 23 839.6 3 850.3 51 389.1 46.4 7.5 16.2 1992 17 467.3 1 624.3 53 764.3 32.5 3.0 9.3 1993 11 430.3 5 106.5 43 812.0 26.1 11.7 44.7 1994 5 330.0 838.0 33 241.0 16.0 2.5 15.7 1995 14 114.3 2 333.0 49 887.0 28.3 4.7 16.5 1996 17 941.8 4 631.5 57 472.0 31.2 8.1 25.8 1997 58 337.0 6 054.0 117 689.0 49.6 5.1 10.4 1998 83 505.0 8 805.0 198 266.0 42.1 4.4 10.5 1988–91 90 939.5 12 021.7 187 566.5 48.5 6.4 13.2 1992–98 208 125.7 29 392.3 554 131.3 37.6 5.3 14.1 1992–96 66 283.7 14 533.3 238 176.3 27.8 6.1 21.9 (1992–98)/ 2.29 2.44 2.95 — — — (1988–91) (1992–96)/ 0.73 1.21 1.27 — — — (1988–91) a See ref. 4. Table 3. New registered drug foreign direct investment (FDI), Thailand, 1992–98a Year Share value in Share value in Total Thai ownership foreign (baht) (baht) ownership (baht) 1992 16 597 800 3 002 200 19 600 000 1993 105 507 000 93 000 105 600 000 1994 150 050 020 31 049 980 181 100 000 1995 36 160 000 11 540 000 47 700 000 1996 212 182 200 129 017 800 341 200 000 1997 39 240 000 2 760 000 42 000 000 1998 138 782 870 4 359 900 143 142 770 1992–98 698 519 890 (79. 4)b 181 822 880 (20.7) 880 342 770 1992–96 520 497 020 (74.9) 174 702 980 (25.1) 695 200 000 a See ref. 4. b Figures in parentheses are % of total share value. 464 Bulletin of the World Health Organization, 2001, 79 (5) Policy and Practice some degree, depending on purchasing power and drug dispensing regulations (Table 6, Fig. 2). Patented drugs Pharmaceutical products in six therapeutic categories were chosen to represent the market situation in respect of patented drugs: antidepressants; antihista- mines and antiallergics; antihyperlipidaemic agents; antiulcerants; broad-spectrum antibiotics; and gastro- intestinal tract regulators. There was no obvious price reduction after the point at which a competitor entered the market. The gap of equivalent prices between original and generic products was varied and unpredictable (Table 7, Fig. 3). Market prices of drugs Market prices of drugs in Thailand are regulated by legal means as well as non-legal mechanisms. Price control is under the jurisdiction of the Ministry of Commerce, which specifies categories of drugs whose prices are to be controlled (Table 8). During the 1997–98 economic crisis it set across-the-board percentage limits on price increases (Table 9). The implementation of price control laws generally targets the list prices of manufacturers and importers and the retail prices charged by pharmacies. The prices of drugs sold through hospitals and clinics are not subjected to legal control. Although private hospitals set their prices independently, retail drug prices in public hospitals are normally no greater than 15% of hospital purchase prices. Since self-medica- tion is common, retail prices of drugs distributed through pharmacies directly affect the affordability of drugs. However, there is no systematic evaluation of the effectiveness of government price regulation of the influence of drug prices on affordability. Wholesale drug prices are influenced by the rules governing public sector procurement and by provincial group purchasing. Collective procurement is effective in price bargaining. In addition, competition among suppliers helps to hold drug prices in check. Because of a lack of overall coordination, however, drug compa- nies charge different prices for the same product procured by different Thai purchasers. Potential effects of TRIPS provisions on pharmaceuticals The following are main problem areas for developing countries with respect to pharmaceuticals as affected by the TRIPS agreement: the limited terms of product and process patents; the short terms of protection; and the broad scope for compulsory licensing and enforcement procedures in national patent systems. The provisions of the TRIPS agreement may need further review in the following areas. Patentability The TRIPS agreement requires WTO members to grant patent protection for a minimum of 20 years for Table 4. Value of manufactured and imported modern medical drugs, Thailand, 1987–98a Year Manufactured Imported Total Imported (baht 6 106) (baht 6 106) (baht 6 106) (%) 1987 5 145.75 2 325.43 7 471.18 31.13 1988 6 708.85 2 570.98 9 279.83 27.71 1989 8 372.85 3 307.60 11 680.45 28.32 1990 8 886.02 3 449.08 13 873.95 30.39 1992 10 696.54 4 682.61 15 379.15 30.45 1993 11 831.03 5 075.31 16 906.34 30.02 1994 12 969.68 6 086.63 19 056.31 31.94 1995 15 820.87 9 276.47 25 097.34 36.96 1996 18 120.41 10 676.01 28 796.42 37.07 1997b 20 221.00 11 255.00 31 476.00 35.76 1998b 20 012.00 11 676.00 31 688.00 36.85 Total 148 442.54 74 597.53 223 040.07 33.45 a See ref. 4. b Preliminary data. Table 5. Comparison of total drug supply and gross national product (GNP) per capita, Thailand, 1987–96a Year Domestic Imported Total drug GNP per Relative rate Relative rate Relative rate drugs drugs supply (Q) capita of change of change of change manufactured (baht 6 106) (baht 6 106) (baht) of Q to of domestic of imported (baht 6 106) income manufactured drugs to drugs to income income 1987 5 145.75 2 325.43 7 471.18 22 960.00 — — — 1988 6 708.85 2 570.98 9 279.83 27 179.00 1.28 1.57 0.60 1989 8 372.85 3 307.60 11 680.45 33 204.00 1.15 1.11 1.26 1990 8 886.02 3 449.08 12 335.10 38 582.00 0.36 0.40 0.28 1991 9 657.54 4 216.41 13 873.95 43 335.00 1.01 0.72 1.73 1992 10 696.54 4 682.61 15 379.15 48 359.00 0.94 0.93 0.96 1993 11 831.03 5 075.31 16 906.34 53 593.00 0.92 0.98 0.78 1994 12 969.68 6 086.63 19 056.31 60 612.00 0.97 0.75 1.47 1995 15 820.87 9 276.47 25 097.34 69 047.00 2.10 1.52 3.19 1996 18 120.41 10 676.01 28 796.42 74 585.00 1.78 1.76 1.82 a See ref. 4. 465Bulletin of the World Health Organization, 2001, 79 (5) Impact of TRIPS on the pharmaceutical industry in Thailand any invention in any branch of technology. This provision is expressly aimed at pharmaceutical products and processes, which most developing countries, as well as some developed countries, do not yet cover in their national patent laws. Because of the high prices of patented drugs and the high costs of research and development in the pharmaceutical field, some countries grant patents only for processes. Through reverse engineering, often used to copy original drugs in countries that do not grant patents for pharmaceutical products, many countries meet their national requirements for drugs at reduced cost and are able to develop their technology at the same time. Other countries with no pharmaceutical industry can buy these drugs at competitive prices but this ability is limited by licence agreements. The TRIPS agreement authorizes certain exclu- sions from patentability, depending on public ethics, especially in connection with the protection of human, animal or plant life, or with the prevention of serious damage to the environment. Member countries may exclude diagnostic, therapeutic and surgical methods for the treatment of humans and animals. Effects of protection or term of patent In many countries, patent protection that lasts 20 years can be expected to result in an increased duration of the patent owner’s monopoly. In the case of pharmaceuticals, the logical consequence of this provision is that drugs can be sold at a relatively high price for longer periods of time. The manufacturers of generic products thus have to wait longer before they can produce the same drugs and sell them at more reasonable prices. Transitional period arrangements TheTRIPS agreement provides for transitional periods during which countries can bring their national legislation and practices into conformity with the terms of the agreement. As far as the substantive rules on patentprotection are concerned, adistinctionwasmade between least developed countries and developing countriesandalsobetweencountrieswithandcountries without a system of patent protection for pharmaceu- ticals whenWTOwas established. As a result, the dates of effectivity of TRIPS are as follows: developed countries, in 1996; developing countries, in 2000 or 2005; and for least developed countries, in 2006. Compulsory licensing The provision in TRIPS for the use of a patented product without authorization of the patent holder Table 6. Market value of pharmaceutical sectors, Thailand, 1992–98a 1992 1993 1994 1995 1996 1997 1998 Market composition Original (baht 6 106) 7 352 9 063 10 558 12 073 14 603 16 728 13 389 Total (baht 6 106) 15 464 17 087 18 555 21 036 24 238 25 000b 25 000b Original (US$6 106) 289 358 420 484 576 533 324 Total (US$6 106) 609 675 738 844 957 797 604 Original/total (%) 47.5 53.0 56.9 57.4 60.2 66.9 53.6 Exchange rate (baht /$US) 25.40 25.32 25.15 24.92 25.34 31.37 41.37 Comparison of originator growth with other key parameters % GDP growth (baht) 8.1 8.5 8.9 8.8 5.5 –0.4 –8.0c Populationc (6106) 57.79 58.34 59.1 59.46 60.12 60.82 61.47 % originator growth (US$) NAd 24 17 15 19 –7 –39 % GODEPCe (US$) NA 22 16 15 18 –9 –40 a See ref. 4. These data were mostly obtained from Pharmaceutical Products Association (PPA) and from direct contact with its president. There were other sources such as the Drug Control Division, Thai Federal Drug Administration. The latter data, however, were not grouped as close to our objectives as those of the PPA. Other key parameters were obtained from the National Accounts Division and the Office of the National Economic and Social Development Board. Monthly reports were obtained from the Bank of Thailand. b Estimate. c Probably underestimated. There may be unregistered persons in remote areas as well as illegal immigrants. d NA = not available. e GODEPC = growth of original drug expenses per capita. 466 Bulletin of the World Health Organization, 2001, 79 (5) Policy and Practice might be understood as equivalent to the compul- sory licence rules used by countries to prevent the abuse of exclusive rights conferred by the patent. However, there are differences between the tradi- tional provisions of compulsory licensing and the TRIPS provision: the former are principally in- tended to serve the public interest, whereas the purpose of the latter is to protect the interests of the rights holder. Exclusive marketing rights Exclusive marketing rights have to be provided by WTO member countries to the applicant for a pharmaceutical patent for at least 5 years during the transitional period. If the application for such a patent was filed after 1995 in a developing country, exclusive marketing rights could be provided before the expiry of the transitional period. This would enable the patent holder to enjoymonopoly rights even if proper patent protection were not granted until after the expiry of the interim period. Burden of proof A new TRIPS agreement rule, relating to the burden of proof in the case of process patents, is also important for member countries. According to the rule, member countries must provide for a reversal of the burden of proof in their legislation. This stipulates that if the holder of a process patent suspects someone of having used the process to obtain an identical product, the person suspected must prove deviations from the patented process. The position of patent holders is thereby strengthened in relation to persons who try to obtain given products through alternative technological routes. Furthermore, the traditional ‘‘innocent until proven guilty’’ maxim is reversed in this instance. Conclusion This analysis of the implications of the TRIPS agreement for the pharmaceutical industry in Thai- Table 7. Pharmaceutical profiles of selected itemsa Generic or chemical Therapeutic No. of Original Imported Generic Other name (dose in mg) categories formsb brand generics copies original substitutesc Amoxycillin + Broad-spectrum antibiotics 4 1 2 4 7 clavulanic acid (375 mg) Ciprofloxacin (250 mg) Broad-spectrum antibiotics 2 1 6 40 7 Cisapride (5 mg) GIT regulators 2 1 0 15d 3 Fluoxetine (20 mg) Antidepressants 3 1 1 18 3 Gemfibrozil (300 mg) Antihyperlipidaemic agents 3 1 1 42d 2 Loratadine (10 mg) Antihistamines and antiallergics 3 1 1 13 2 Omeprazole (20 mg) Antiulcerants 3 1 2 19 1 Roxithromycin (150 mg) Broad-spectrum antibiotics 2 1 2 36 5 a See ref. 4. The data were last updated on 20 April 1999 from Thai Federal Drug Administration. b Different forms. In any one form there may be different concentrations, different sizes and different packaging. c Other originals in the same drug class that are used in a rather loose clinical meaning. d One generic firm was contracted to produce the original brand for the originator company. 467Bulletin of the World Health Organization, 2001, 79 (5) Impact of TRIPS on the pharmaceutical industry in Thailand land is merely the starting point for a continuing process. Ongoing changes in the structure of the economy, regulations, patent laws and a myriad of other factors mean that further study and action will be needed. The TRIPS provisions relating to patentability, the effects of protection or term of patents, transitional period arrangements, compul- sory licensing, exclusive marketing rights, and the burden of proof will require further review. The Thai government, the private sector and the population in general should prepare themselves for the consequences of the country’s Patent Drug Act. In both the short and the long term, some economic disadvantages are expected for the Thai pharmaceutical industry. Each country has specific, sometimes unique, characteristics and needs. Domestic laws and regulations therefore have to be changed in order to match national conditions and help to orientate the pharmaceutical industry in a desirable way, while allowing compatibility with international agree- ments. The present study does not reveal any price change due to the patent protection act and does not provide strong evidence of FDI and technology transfer. In anticipation of price movement or low- grade technology transfer, the study proposes that some aspects of the existing Patent Act be changed — in particular, that attention be given to the following: the term or duration of patent protection; non-patentable subject matter; the rights and privileges of patentees; import monopoly; non- voluntary licences unrelated to non-working patents; the definition of working and non-working patent; actions against non-working patents (e.g. provision for revocation or forfeiture of patent); stipulation on conditions promoting technology transfer; the repeal of any disadvantageous interim measures; and regulatory mechanisms. Bolar provision (early working) is an another exception specifically applic- able to pharmaceutical patents — it relates to using an invention without the patentee’s authorization for the purpose of obtaining approval of a generic product before the patent expiration date (6). An appropriate time frame for effective action and the extent to which patent laws are implemented and practised would undoubtedly help to alleviate the economic burden of buying more expensive drugs. In the long run, Thailand should endeavour to learnmore from other countries before fully committing itself to new aspects of more progressive intellectual property protection, e.g. patent term extension. Above all, the involvement of the government is extremely impor- tant if progressive development is to be ensured. The pharmaceutical industry has not received enough consideration and national authorities should have a clear vision for this industry and should understand the implications for health if they do nothing. Lessons learnt from other countries and continuing study can be expected to lead to solutions appropriate to conditions in Thailand. The provision and revision of pharmaceutical policies should not only conform to present standards in the industry and to international commitments but should also ensure an improved quality of life for the Thai people as a whole. Recommendations In the long run, only the strongest companies are likely to survive in the Thai pharmaceutical market. However, it is doubtful whether many of them will Table 8. Drug categories subject to Thai Ministry of Commerce price controla Category Active ingredient Antiflatulents Sodium bicarbonate Phenyl salicylate Asafoetida Antacids Aluminium hydroxide Antidiarrhoeals Oral rehydration salt Loperamide Diplenoxylate + atropine Antitussives/expectorants/mucolytics Glycyrrhiza fluid extract Dextromethorphan Bromhexine salt Acetylcysteine Glyceryl guaiacolate Cold preparations Paracetamol and chlorpheniramine maleate and phenylpropanolamine Analgesics/antipyretics Aspirin (acetylsalicylic acid ) Paracetamol Anthelmintics Albendazole Mebendazole Niclosamide Antibacterials Gentamicin Topical preparations Sulfanilamide Tetracycline and derivatives Oral preparations Ampicillin Amoxicillin Co-trimoxazole Penicillin V Tetracycline and/or derivatives Antifungals Clotrimazole Topical preparations Isoconazole Miconazole Salicylic acid Tolnaftate Antiallergics/antipruritics Betamethasone Topical preparations Calamine Prednisolone Triamcinolone Antiinflammatories Diclofenac Topical preparations Methyl salicylate Piroxicam Mucopolysaccharide polysulfate Inhalers Menthol Eucalyptus oil Lozenges Cetylpyrdinium chloride Dequalinium chloride Dichlorobenzyl alcohol Tyrothricin Neomycin and/or bacitracin Menthol and/or eucalyptol a See ref. 5. 468 Bulletin of the World Health Organization, 2001, 79 (5) Policy and Practice be Thai-owned. In anticipation of future market conditions, therefore, Thai companies should focus on those areas where they are most skilful. Many chemicals are still not covered by patent law, and the development of drugs from these chemicals is there- fore potentially profitable for local pharmaceutical industries. Full drug development is expensive and currently unrealistic, not only for Thai companies but also for those in many other countries that are not research-based. Thailand would gain by investing in areas where it is relatively competent and where benefits are likely to be obtained for society as a whole. At the same time, key players in the health sector have to prepare themselves for a new era of competition. As aMember ofWTO, Thailand has to comply with themandates set forth in the TRIPSAgreement. With a view to alleviating the potentially negative impact of such compliance we propose a strategy with the following components. . An innovative purchaser strategy to establish rational cost-effective drug selection procedures for public and private health care facilities and to create a government financing system for drugs and other aspects of health care. . A prescriber and dispenser strategy to promote the rational use of drugs in health facilities and encourage the prescribing of generic drugs. Both national and multinational firms should be urged to develop an agreed set of business practices to ensure maximum benefit for the public and punish the unethical promotion of medicine. . A producer strategy to support and encourage technical transfers of drug development processes to Thailand, to provide truthful information allowing doctors and patients to make the best and most efficient use of medicine, and to bridge the gap between developing and developed countries through ‘‘pharmacophilanthropy’’. . A product strategy promoting research into and the developmentof traditionalmedicines soas to reduce dependence on modern drugs and strengthen the country’s capacity for innovation. This would also facilitate participation in the modern drug devel- opment process, with accompanying enhancement of indigenous technical, personnel, financing, patenting, research and related capabilities, and would help to streamline and simplify patent registration of potential compounds. . An effective price control system taking global drug prices into consideration. Prices for new drugs protected under patents should be set on a reasonable basis and subsidized where necessary in order to make essential drugs accessible to all segments of the population. Direct legal control of drug prices might be necessary if standard means of price regulation were ineffective. . A patent-to-third-party strategy. The TRIPS Agreement permits compulsory licensing. For example, in order to protect public health and nutrition the government could grant a patent to a third party without the consent of the original patent holder. . Parallel imports could theoretically be used in a national strategy for restoring price competition for patented products, including pharmaceuticals, by allowing the importation of identical patented products at reduced prices. . A power-of-the-customer strategy, recognizing the need for countries to accept that, as world citizens, all people share the price burden of drug research and discovery. However, governments can play a key role in educating people on how to avoid illness by reducing risks, adopting preven- tive health care, and avoiding the irrational and unnecessary use of drugs. . Research and development. It is proposed that the Thai Government use a tax on drug sales to build capacity for developing patentable new drugs and strengthen price and patent management and monitoring systems. . Personnel strategy. The Thai Government should provide better education, training, development and support in highly technical skills to ensure adequate human resources in the area of research and development. It should also create a fair incentive system in order to maintain these scarce human resources, stop the brain drain and encourage Thai scientists and experts living abroad to return home. . Prevention strategy. Primary care and preventive medicine should form the keystones of national health policy. Preventive measures and healthy lifestyles can be expected to diminish the demand formedical care and improve the quality of life in a relatively cost-effective fashion. n Acknowledgement We wish to acknowledge the financial support provided for this study by WHO’s South-East Asia Regional Office. Conflicts of interest: none declared. Table 9. Permitted percentage price increases from present level for three categories of pharmaceutical product in response to Thai currency devaluationa Drug categories % increase 1 October 1997 25 March 1998 Imported finished products 18.89 7.75 Repackaged products 17.15 6.91 Locally manufactured products 17.15 6.95 a Data from: Ministry of Commerce, Department of Internal Trade, Division of Industrial Goods 1, Bangkok, 1999. 469Bulletin of the World Health Organization, 2001, 79 (5) Impact of TRIPS on the pharmaceutical industry in Thailand Re´sume´ Impact de l’Accord de l’Organisation mondiale du Commerce sur les ADPIC sur l’industrie pharmaceutique en Thaı¨lande L’Accord sur les aspects des droits de proprie´te´ intellectuelle qui touchent au commerce (ADPIC) adopte´ en 1994 par l’Organisation mondiale du Commerce (OMC) a e´tabli des normes minimales universelles dans tous les domaines de la proprie´te´ intellectuelle. Il est pre´vu de faire appliquer ces normes partout dans le monde par le biais d’un me´canisme approprie´. Le pre´sent article propose une strate´gie pour atte´nuer les effets potentiellement ne´gatifs de l’Accord sur les ADPIC en Thaı¨lande concernant les acheteurs, les prescripteurs et dispensateurs, les producteurs, les produits, le controˆle des prix, la de´livrance de brevets a` des tiers, les importations paralle`les, le pouvoir des consommateurs, les nouveaux me´dicaments brevetables, le personnel et les politiques de pre´vention. Les dispositions ci-apre`s de l’Accord sur les ADPIC inte´ressent tout particulie`rement l’industrie pharmaceutique en Thaı¨lande : la dure´e limite´e des brevets de produit et de proce´de´ ; les conditions de la protection, et la large place donne´e a` l’octroi de licences obligatoires et aux proce´dures visant a` faire respecter les droits dans le syste`me national de brevets. Resumen Repercusio´n del Acuerdo sobre los ADPIC de la Organizacio´n Mundial del Comercio en la industria farmace´utica de Tailandia En el Acuerdo de la Organizacio´n Mundial del Comercio de 1994 sobre los Aspectos de los Derechos de Propiedad Intelectual relacionados con el Comercio (ADPIC) se establecieron normas universales mı´nimas en todas las a´reas de la propiedad intelectual. El acuerdo aspira a aplicar esas normas a nivel mundial mediante un mecanismo coercitivo de la OMC. En el presente artı´culo se propone una estrategia para paliar las repercusiones potencialmente negativas de los ADPIC en Tailandia en relacio´n con lo siguiente: compradores; prescriptores y dispensadores; productores; productos; control de pre- cios; patentes a terceros; importaciones paralelas; poder del cliente; medicamentos nuevos patentables; personal, y polı´ticas de prevencio´n. Las siguientes disposiciones de los ADPIC son pertinentes para la industria farmace´utica en Tailandia: la duracio´n limitada de las patentes de productos y procesos; las condiciones de proteccio´n; y el amplio margen para el re´gimen vinculante de concesio´n de licencias y los procedimientos de vigilancia del cumplimiento en el sistema nacional de patentes. References 1. Kakazu H. Industrial technology capacities and policies in Asian developing countries. Asian Development Review, 1996, 8 (2): 46–76. 2. Kraipornsak P. Factors affecting total factor productivity growth. Chulalongkorn Journal of Economics, 1995, 7 (3): 343–360. 3. Pongpisanupichit J et al. Direct foreign investment and capital flow. Background paper for the 1989 TDRI Year-end Conference on Thailand in the International Economic Community. Bangkok, Thailand Development Research Institute, 1989. 4. Supakankunti S et al. Study of the implications of the WTO TRIPS Agreement for the pharmaceutical industry in Thailand. Paper presented to: Regional Consultation on WTO Multilateral Trade Agreements and their Implications on Health — TRIPS, Bangkok, 16–18 August 1999. 5. Report of the Seminar on Drug Price Problems and Government Regulation. Bangkok, Department of Internal Trade, 1994. 6. Correa C. Integrating public health concerns into patent legislation in developing countries. Geneva, The South Centre, 2000. 470 Bulletin of the World Health Organization, 2001, 79 (5) Policy and Practice